Protara Therapeutics (NASDAQ:TARA) PT Raised to $30.00

Protara Therapeutics (NASDAQ:TARA) had its price objective increased by Oppenheimer from $26.00 to $30.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 8th.

Protara Therapeutics Stock Down 1.6 %

Shares of TARA stock opened at $3.00 on Monday. Protara Therapeutics has a 12-month low of $1.04 and a 12-month high of $5.24. The company has a market capitalization of $34.29 million, a P/E ratio of -0.84 and a beta of 1.71. The firm has a 50-day moving average price of $3.76 and a 200 day moving average price of $2.48.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.13. As a group, research analysts expect that Protara Therapeutics will post -3.56 earnings per share for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.